Annual EBITDA
-$14.58 M
-$2.48 M-20.55%
31 December 2023
Summary:
Acurx Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$14.58 million, with the most recent change of -$2.48 million (-20.55%) on 31 December 2023. During the last 3 years, it has fallen by -$9.98 million (-216.91%). ACXP annual EBITDA is now -216.91% below its all-time high of -$4.60 million, reached on 31 December 2020.ACXP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.82 M
+$1.30 M+31.54%
30 September 2024
Summary:
Acurx Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.82 million, with the most recent change of +$1.30 million (+31.54%) on 30 September 2024. Over the past year, it has increased by +$293.40 thousand (+9.42%). ACXP quarterly EBITDA is now -208.91% below its all-time high of -$913.40 thousand, reached on 30 June 2020.ACXP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$16.44 M
+$293.40 K+1.75%
30 September 2024
Summary:
Acurx Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$16.44 million, with the most recent change of +$293.40 thousand (+1.75%) on 30 September 2024. Over the past year, it has dropped by -$3.71 million (-29.18%). ACXP TTM EBITDA is now -1184.96% below its all-time high of -$1.28 million, reached on 01 March 2020.ACXP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACXP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -20.6% | +9.4% | -29.2% |
| 3 y3 years | -216.9% | +39.2% | -45.7% |
| 5 y5 years | - | - | - |
ACXP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -216.9% | at low | -7.7% | +44.8% | -45.7% | +1.8% |
| 5 y | 5 years | -216.9% | at low | -208.9% | +44.8% | -1185.0% | +1.8% |
| alltime | all time | -216.9% | at low | -208.9% | +44.8% | -1185.0% | +1.8% |
Acurx Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.82 M(-31.5%) | -$16.44 M(-1.8%) |
| June 2024 | - | -$4.12 M(-5.8%) | -$16.73 M(+4.2%) |
| Mar 2024 | - | -$4.38 M(-14.4%) | -$16.05 M(+10.1%) |
| Dec 2023 | -$14.58 M(+20.5%) | -$5.11 M(+64.2%) | -$14.58 M(+14.6%) |
| Sept 2023 | - | -$3.12 M(-9.6%) | -$12.72 M(-3.2%) |
| June 2023 | - | -$3.45 M(+18.7%) | -$13.15 M(+6.7%) |
| Mar 2023 | - | -$2.90 M(-11.0%) | -$12.33 M(+1.9%) |
| Dec 2022 | -$12.09 M | -$3.26 M(-7.9%) | -$12.09 M(+5.5%) |
| Sept 2022 | - | -$3.54 M(+35.1%) | -$11.46 M(-8.8%) |
| June 2022 | - | -$2.62 M(-1.9%) | -$12.56 M(-10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$2.67 M(+1.6%) | -$14.01 M(+9.3%) |
| Dec 2021 | -$12.81 M(+178.6%) | -$2.63 M(-43.4%) | -$12.81 M(+13.6%) |
| Sept 2021 | - | -$4.64 M(+14.0%) | -$11.28 M(+41.8%) |
| June 2021 | - | -$4.07 M(+176.1%) | -$7.95 M(+65.8%) |
| Mar 2021 | - | -$1.47 M(+34.9%) | -$4.80 M(+4.2%) |
| Dec 2020 | -$4.60 M(-22.4%) | -$1.09 M(-16.9%) | -$4.60 M(+31.2%) |
| Sept 2020 | - | -$1.31 M(+43.9%) | -$3.51 M(+60.0%) |
| June 2020 | - | -$913.40 K(-28.6%) | -$2.19 M(+71.4%) |
| Mar 2020 | - | -$1.28 M | -$1.28 M |
| Dec 2019 | -$5.93 M | - | - |
FAQ
- What is Acurx Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Acurx Pharmaceuticals?
- What is Acurx Pharmaceuticals annual EBITDA year-on-year change?
- What is Acurx Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Acurx Pharmaceuticals?
- What is Acurx Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Acurx Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Acurx Pharmaceuticals?
- What is Acurx Pharmaceuticals TTM EBITDA year-on-year change?
What is Acurx Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ACXP is -$14.58 M
What is the all time high annual EBITDA for Acurx Pharmaceuticals?
Acurx Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.60 M
What is Acurx Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ACXP annual earnings before interest, taxes, depreciation & amortization has changed by -$2.48 M (-20.55%)
What is Acurx Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ACXP is -$2.82 M
What is the all time high quarterly EBITDA for Acurx Pharmaceuticals?
Acurx Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$913.40 K
What is Acurx Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ACXP quarterly earnings before interest, taxes, depreciation & amortization has changed by +$293.40 K (+9.42%)
What is Acurx Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ACXP is -$16.44 M
What is the all time high TTM EBITDA for Acurx Pharmaceuticals?
Acurx Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.28 M
What is Acurx Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ACXP TTM earnings before interest, taxes, depreciation & amortization has changed by -$3.71 M (-29.18%)